Tocainide detailed information
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Bioavailability | 0.9-1 (oral) |
Protein binding | 10-20% |
Metabolism | glucuronidation (primary) |
Elimination half-life | 9-14 R, 13-20 S |
Excretion | 30-50% urine (unchanged) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C11H16N2O |
Molar mass | 192.258 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here
Overview
Tocainide (Tonocard®) is a class Ib antiarrhythmic agent. It is no longer sold in the United States.
Quick look at the Pharmacokinetics
Tocaine is a lidocaine analog, that does not have significant 1st pass metabolism. It is found in two enantiomers. The R isomer is 4x as potent as the S. Oral bioavaliability is 0.9-1.0. In the blood tocainide is 10-20% protein bound. The Volume of distribution is 2.5-3.5 L/kg. 30-50% is excreted unchanged in the urine. The more active R-isomer is cleared faster in anephric patients or those with severe renal dysfunction. The main metabolite is the glucuronidated tocainide carbamic acid. The glucuronosyl transferase is apparently induced by rifampin. Weak inhibition of Cyp1A2 leads to a mild theophylline interaction. (Not verbatim)
External links
Burton ME. Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antiarrhythmic agents
- Drugs